NCT01019941已完成1 期
Open Label, Randomized, Single-dose, Crossover Study to Evaluate the Pharmacokinetics of Docetaxel Between Two Docetaxel Products, CKD-810 and Taxotere Inj., in Patients With Advanced Solid Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 44
- 试验地点
- 7
- 主要终点
- Pharmacokinetics of CKD-810 and Taxotere inj.
研究概览
简要总结
The purpose of this study is to evaluate safety and the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer.
详细描述
This is a Phase III study designed to evaluate the pharmacokinetic characteristics of docetaxel between two docetaxel products in patients with advanced solid cancer. This study will also assess the safety of the docetaxel in advanced solid cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient is greater than 18 years of age
- •Advanced solid tumor
- •locally advanced or metastatic breast cancer which docetaxel alone therapy was adequate
- •locally advanced or metastatic non-small cell lung cancer which docetaxel alone therapy was adequate
- •locally advanced or metastatic other malignant tumor which docetaxel alone therapy was adequate
- •Patient has a life expectancy of at least 3 months
- •Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2
- •Absolute neutrophil count ≥ 1,500/㎣
- •Platelet count ≥ 100,000/㎣
- •Hemoglobin ≥ 9.0g/dL
- •Total Bilirubin ≤ 1.5 X ULN
- •Alkaline Phosphatase ≤ 2.5 X ULN
- •AST/ALT ≤ 2.0 X ULN
- •Serum creatinine ≤ 1.5 X ULN or Creatinine clearance ≥ 60mL/min(Cockcroft equation)
- •Patients should voluntarily sign a written informed consent before study entry
排除标准
- •If present, any active bacterial infection that have to parenteral antibiotic therapy. Patients may be included if their infection has resolved to totally or controlled state
- •Brain metastasis with neurologic symptom
- •History of unstable cardiac arrhythmia, congestive heart failure or myocardial infarction within 6 months
- •Known to test positive for HIV or hepatitis B or C
- •Use of inducers or inhibitors of CYP3A4 within 2 weeks prior to the first dose of study medication. (Patients may be included if the patients who need to intake the medication such as cimetidine was keep the same dose continuously at 1 cycle and 2 cycle)
- •Peripheral neuropathy ≥ Grade 2
- •known resistant or uncontrolled severe hypersensitivity to docetaxel
- •History of hypersensitivity reaction to Polysorbate 80
- •The female patients of pregnancy, breast feeding or childbearing potential. And the patients has not laboratory result or the result was a positive serum pregnancy test, also Patients (M/F) with reproductive potential not implementing adequate contraceptive measurements. (In case of menopausal women, keeping menopause at least 12 months. All sexually active male patients must agree to use adequate methods of birth control throughout the study)
- •Administration of any other tumor therapy, including chemotherapy, radiotherapy, and immunotherapy within 4 weeks before the beginning of study treatment. Patients may be included if the radiotherapy was conducted to relieve symptoms and that symptoms recovered to grade 1
- •treated with any investigational drugs within 4 weeks before the beginning of study treatment
- •Must be treated concurrent administration of other anti-cancer medicine
- •Not able to participate to the study, at the discretion of the investigator
研究组 & 干预措施
1st cycle:CKD-810 -> 2nd cycle:Taxotere inj.
Other
干预措施: CKD-810, Taxotere inj. (Drug)
1st cycle:Taxotere inj.-> 2nd cycle:CKD-810
Other
干预措施: CKD-810, Taxotere inj. (Drug)
结局指标
主要结局
Pharmacokinetics of CKD-810 and Taxotere inj.
时间窗: 2 Cycles
次要结局
- Safety of CKD-810 and Taxotere inj.(2 Cycles)
研究者
研究点 (7)
Loading locations...
相似试验
终止
2 期
A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate CancerProstatic Neoplasms, Castration-ResistantNCT05169684Bristol-Myers Squibb10
撤回
1 期
Oral Docetaxel in Patients With Normal or Impaired Liver FunctionSolid Tumor, AdultImpaired Liver FunctionNCT05084456Modra Pharmaceuticals
已完成
3 期
Taxotere (Docetaxel) New Indication: Squamous Cell Carcinoma of the Head and Neck (SCCHN) Treatment Registration TrialHead and Neck NeoplasmsNCT00995293Sanofi240
终止
3 期
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell CarcinomaCarcinoma, Non-small Cell LungNCT02775006The Netherlands Cancer Institute45
招募中
2 期
The Efficacy and Safety of Docetaxel Combined With Platinum for Metastatic Hormone-sensitive Prostate CancerHormone Sensitive Metastatic Prostate CancerDNA Damage Repair DeficiencyChemotherapy EffectChemotherapeutic ToxicityNCT05461261The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School50